Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890467 | 0.98 | MAOA (0.52) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL4890477 | 0.91 | SIGMAR1 (0.48) | SIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL9825321 | 0.82 | SIGMAR1 (0.56) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL3973128 | 0.81 | ALDH1A1 (0.48) | MAOAMAOBL3MBTL1 | |
| SCHEMBL8095284 | 0.81 | SIGMAR1 (0.71) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL8094527 | 0.81 | SIGMAR1 (0.71) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL6546948 | 0.81 | SIGMAR1 (0.71) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL2823250 | 0.81 | SIGMAR1 (0.71) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL8085946 | 0.81 | SIGMAR1 (0.71) | SIGMAR1MAOAMAPTRXFP1MAOB | |
| SCHEMBL1433686 | 0.81 | SIGMAR1 (0.71) | SIGMAR1MAOAMAPTRXFP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| EP-1869051-A1 | 4-PIPERAZINYLTHIENO Ý2,3-D¨PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006103545-A1 | 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | SIGMAR1 1885/4885MAOA 1106/4885MAPT 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.